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Brief CommunicationsVasopressin to attenuate pulmonary hypertension and improve systemic
blood pressure after correction of obstructed total anomalous
pulmonary venous return
Mark A. Scheurer, MD, Scott M. Bradley, MD, and Andrew M. Atz, MD, Charleston, SCPulmonary hypertension remains a major contributor tomorbidity in the postoperative course of patients aftersuccessful surgical correction of obstructed total anom-alous pulmonary venous return (TAPVR). Additionally,
the postcardiotomy syndrome of low systemic vascular resistance
and low cardiac output often necessitates aggressive vasopressor
and inotropic support. Vasopressin has been prospectively shown
in both adults and children to decrease the need for vasoactive
medications in the postcardiotomy syndrome. In animal models of
hypoxic pulmonary constriction, vasopressin has been shown to
have properties of pulmonary vasodilation as well as systemic
vasoconstriction. We hypothesized that vasopressin might de-
crease pulmonary vascular resistance (PVR) and thus decrease the
need for vasoactive medications after surgical correction of
TAPVR.
Clinical Summaries
PATIENT 1. A 36-week gestation 2.3-kg female infant with
obstructed supracardiac TAPVR underwent complete repair on the
second day after birth. After weaning from cardiopulmonary by-
pass, pulmonary arterial pressure (PAP) increased to suprasys-
temic levels. Nitric oxide (NO) was initiated at 40 ppm. On arrival
in the pediatric cardiac intensive care unit, the patient had a PAP
of 51/21 mm Hg (65% systemic) and was receiving dopamine (10
g · kg1 · min1), epinephrine (0.03 g · kg1 · min1), and
milrinone (0.5 g · kg1 · min1). Management included hyper-
ventilation, hyperoxygenation, paralysis, and sedation. Epineph-
rine was gradually increased to 0.1 g · kg1 · min1 to treat
systemic hypotension. PAP concomitantly increased to near sys-
temic levels and was treated by increasing NO to 60 ppm. At 20
hours after the patient’s arrival in the unit, vasopressin was initi-
ated at 0.0003 units · kg1 · min1 (Figure 1). Within 1 hour, PAP
had decreased to 55% of systemic levels, and systemic blood
pressure had increased from 55 to 85 mm Hg. An echocardiogram
on postoperative day 1 showed a widely patent pulmonary venous
anastomosis site. Vasopressin was titrated upward to a maximal
dose of 0.0012 units · kg1 · min1. Epinephrine was rapidly
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PAP remained between 55% and 75% of systemic during this
period. After 82 hours, vasopressin was discontinued because of
hyponatremia (117 mmol/L). No elevation in PAP was noted after
discontinuation of vasopressin. Sodium levels returned to normal
within the next 24 hours. NO was stopped within 24 hours after
vasopressin discontinuation with no rebound pulmonary hyperten-
sion. The child was extubated on postoperative day 10 and was
discharged on postoperative day 22. At 13.5 months of age, the
child is thriving with no evidence of recurrent pulmonary venous
obstruction or pulmonary hypertension.
PATIENT 2. A term 3.4-kg male infant with obstructed infrac-
ardiac TAPVR underwent surgical correction on the first day after
birth. The patient was successfully weaned from cardiopulmonary
bypass. PAP was initially systemic, and NO at 20 ppm was
initiated. On arrival in the pediatric cardiac intensive care unit, the
patient had a PAP of 58/26 mm Hg (80% systemic) and was
receiving dopamine (10 g · kg1 · min1) and milrinone (0.5 g
· kg1 · min1). Management included hyperventilation, hyper-
oxygenation, paralysis, and sedation. Epinephrine was initiated at
0.02 g · kg1 · min1 for systemic hypotension. As PAP rose to
near systemic levels 2 hours later, vasopressin was initiated at
0.0003 units · kg1 · min1 and epinephrine was turned off.
Within 1 hour, PAP had decreased to 60% of systemic and sys-
temic blood pressure had stabilized. An echocardiogram on post-
operative day 1 showed a widely patent pulmonary venous anas-
tomosis site. Vasopressin was titrated upward to a maximal dose of
0.0012 units · kg1 · min1. After 60 hours, vasopressin was
discontinued because of hyponatremia (119 mmol/L). No elevation
in PAP was noted after discontinuation of vasopressin. Sodium
levels returned to normal within the next 36 hours. NO was
stopped within 72 hours after vasopressin discontinuation with no
rebound pulmonary hypertension. The child was extubated on
postoperative day 8 and was discharged on postoperative 18. At 13
months of age, the child is thriving with no evidence of recurrent
pulmonary venous obstruction or pulmonary hypertension.
Discussion
Previous reports have shown that vasopressin is an effective agent
in adults to decrease systemic vasopressor requirements with post-
cardiotomy syndrome.1 In children with congenital heart disease
and postoperative vasodilatory shock, one case series similarly
showed a decrease in inotropic scores immediately after initiation
of continuous vasopressin.2 In that series, changes in PVR or PAP
were not reported outcomes. In adult series, PAP during vasopres-
sin infusion has variously been reported as being either unchanged
or decreased, with no significant changes in PVR.1 A collection of
animal experiments has shown that vasopressin selectively vaso-
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Brief Communicationsdilates pulmonary vasculature under hypoxic conditions through a
V1 receptor–mediated release of NO.3,4 Additionally, a model of
chronic hypoxia suggests that the selective pulmonary vasodilatory
action of vasopressin is enhanced through altered receptor-mediated
processes during prolonged hypoxia.5
We hypothesized that in patients with high risk of vasodilatory
shock, a history of a significant hypoxic insult, and coincident
pulmonary hypertension (such as infants after repair of obstructed
TAPVR) vasopressin would be an effective agent to decrease the
need for vasopressor support and to ameliorate pulmonary hyper-
tension. The 2 cases presented here demonstrate that the initiation
of vasopressin can dramatically decrease PAP and increase sys-
tolic blood pressure, allowing the decrease of vasopressor infu-
sions. Although no direct measurements of PVR or cardiac output
Figure 1. Continuous traces of systemic blood pressure
diastolic) recorded every minute in patient 1. Despit
elevated PAP. Continuous infusion of vasopressin (0
additional decrease in PAP and improved systemic blwere obtained during this study, left atrial pressures remained the
The Journal of Thoracisame, and no increase in lactic acidosis ensued after the initiation
of vasopressin. Most importantly, the decreases in PAP were noted
during a period of otherwise maximized medical therapy for pul-
monary hypertension.
The use of a vasopressin infusion does have limitations, such as
the hyponatremia noted in these cases. These decreases in sodium
were gradual and transient and did not result in clinical seizures.
Continuous electroencephalographic monitoring was not performed,
however, so the presence of subclinical seizures cannot be excluded.
We have found that vasopressin can have an important tempo-
rizing role in the control of pulmonary hypertension and systemic
hypotension after obstructed TAPVR repair. Measurement of ar-
ginine vasopressin levels before and after initiation of vasopressin,
as well as calculation of cardiac output and PVR, would be
olic, mean, and diastolic), and PAP (systolic, mean and
atment with NO at 60 ppm, patient had persistently
units/[kg · min], initiated at vertical line) caused
ressure.(syst
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Brief Communicationsshould be used when using vasopressin beyond 24 hours, because
significant hyponatremia may ensue.
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Extended pericardiotomy avoids cardiopulmonary
bypass during bilateral sequential lung
transplantation
Takahiro Oto, MD, Marc Rabinov, FRACS, Franklin Rosenfeldt, FRACS, andBilateral-sequential lung transplantation (BSLTx)through a clamshell thoracotomy has made the proce-dure of double-lung replacement possible without theuse of cardiopulmonary bypass (CPB).1 Avoiding CPB
has the potential advantages of reducing early allograft dysfunc-
tion2 and coagulopathy, as well as lessening the amount of blood
transfusion.3 CPB is always required during lung transplantation
for pulmonary hypertensive lung diseases or nonpulmonary hyper-
tensive lung diseases with concomitant cardiac repair. However,
CPB is also occasionally required during lung transplantation for
inadequate gas exchange, right-heart dysfunction, or hemody-
namic instability caused by mediastinal manipulation during sin-
gle-lung ventilation.2 For patients with pulmonary fibrosis (PF)
undergoing BSLTx, adhesions and reduced size of the pleural
space might necessitate forceful mediastinal manipulation to ac-
cess the left hilum. This might cause severe hemodynamic com-
promise, despite inotropic support and inhaled nitric oxide. Un-
planned CPB might be required, especially when the patients with
PF have preexisting pulmonary hypertension (PH). To avoid he-
modynamic instability during mediastinal manipulation, we pos-
tulated that extending the pericardiotomy might release the right
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prove cardiac function, and
avoid the necessity of CPB.
We have performed this pro-
cedure in 3 patients with
moderate PH caused by PF
and succeeded in all 3 in
avoiding the unplanned use
of CPB.
Clinical Summary
Between March 1990 and May 2004, a total of 500 lung trans-
plantations were performed at the Alfred Hospital, and of these,
239 were BSLTx procedures (Figure 1). Six of 21 patients with PF
had severe preexisting PH; that is, the ratio of pulmonary artery
pressure (PAP) to systemic blood pressure (PAP/AoP) was more
than 0.8, and planned CPB was performed. For the 15 patients with
moderate PH (PAP/AoP ratio of0.8), CPB was on standby in the
operating room and was initiated when needed. All 15 patients had
an acceptable hemodynamic status approximately 10 minutes after
clamping of the left pulmonary artery. All 10 patients with PAP/
AoP ratios of less than 0.5 did not require CPB to complete the
procedure. For the 5 patients with PAP/AoP ratios of between 0.5
and 0.8 (Table 1), severe hemodynamic instability resulted from
mediastinal manipulation to access the left hilum and pulmonary
ligament during the left-side procedure. Efforts made to avoid CPB
included use of inotropic drug infusions (epinephrine or norepi-
nephrine up to 2.5 g · kg-1 · min-1), vasodilators (sodium nitro-
prusside, nitroglycerin, or prostacyclin), and inhaled nitric oxide
(40 ppm). Despite these treatments, PAP and central venous pres-
sure increased with decreased AoP in all 5 patients, and initiation
of CPB seemed to be unavoidable to complete the procedure. In
the first 2 patients of this series, CPB was immediately initiated;
however, in the last 3 patients, we elected to perform a long-
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